Devising a viable global strategy to combat Cholera
BioSpectrum Asia|BioSpectrum Asia June 2023
Since mid-2021, the world is facing an acute upsurge of the 7th cholera pandemic characterised by the number, size and concurrence of multiple outbreaks, the spread to areas free of cholera for decades and alarming high mortality rates. Based on the current situation and lack of vaccines and other resources, the World Health Organisation (WHO) assesses the risk at the global level as very high.
Devising a viable global strategy to combat Cholera

For reasons not yet fully understood, beginning in 2022 the world experienced an unprecedented surge in cholera outbreaks as characterised by the number, size and concurrence. Cholera is an acute, rapidly dehydrating diarrheal disease transmitted through water or food contaminated with the bacteria Vibrio cholerae O1. It is a disease of poverty, primarily affecting people living in areas without access to safe drinking water and inadequate sanitation.

The global burden of cholera is not fully known because of under-reporting, with some affected countries not reporting cases at all to avoid the stigma. One study estimates 1.3 billion people are at risk for cholera in a total of 69 endemic countries, with 2.86 million cholera cases and an estimated 95,000 deaths annually. Most of the global burden is in sub-Saharan Africa (60 per cent ) and South-East Asia (29 per cent ).

In January 2023, WHO declared cholera to be a grade 3 global emergency, the highest risk level. As of March, there were 24 countries reporting outbreaks, a number expected to increase as most countries are not yet in the high transmission season. The Steering Committee of the Global Task Force on Cholera Control (GTFCC) issued a statement that climate change multiplies the risk of cholera around the world, and the upsurge beginning in 2022 may be the new normal.

Unfortunately, the current global supply of vaccines is insufficient to meet the ongoing surge in outbreaks. As a result of the strained global cholera vaccine supply, in late 2022, the WHO International Coordinating Group (ICG), the body which manages emergency supplies of vaccines, temporarily suspended the standard two-dose vaccination schedule in cholera outbreaks and recommended a single dose instead. This strategy, while expanding the coverage of vaccines to a larger population, may be associated with reduced protection in young children.

Diese Geschichte stammt aus der BioSpectrum Asia June 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der BioSpectrum Asia June 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIOSPECTRUM ASIAAlle anzeigen
Inventia announces groundbreaking advancement in 3D cell culture technology
BioSpectrum Asia

Inventia announces groundbreaking advancement in 3D cell culture technology

Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.

time-read
1 min  |
March 2025
Aphra names Justin Untersteiner as CEO
BioSpectrum Asia

Aphra names Justin Untersteiner as CEO

The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).

time-read
1 min  |
March 2025
WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
BioSpectrum Asia

WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls

The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.

time-read
1 min  |
March 2025
Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
BioSpectrum Asia

Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services

Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.

time-read
1 min  |
March 2025
PanopticAI gets US FDA clearance for contactless vital signs monitoring software
BioSpectrum Asia

PanopticAI gets US FDA clearance for contactless vital signs monitoring software

PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.

time-read
1 min  |
March 2025
Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
BioSpectrum Asia

Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.

time-read
1 min  |
March 2025
Axel Klarmeyer joins as CEO at Chamlion International
BioSpectrum Asia

Axel Klarmeyer joins as CEO at Chamlion International

China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.

time-read
1 min  |
March 2025
World Bank supports Bosnia and Herzegovina in strengthening healthcare
BioSpectrum Asia

World Bank supports Bosnia and Herzegovina in strengthening healthcare

The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).

time-read
1 min  |
March 2025
GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
BioSpectrum Asia

GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs

The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.

time-read
1 min  |
March 2025
NIH to lead implementation of National Plan to End Parkinson's Act in US
BioSpectrum Asia

NIH to lead implementation of National Plan to End Parkinson's Act in US

With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.

time-read
1 min  |
March 2025